Using drug repositioning, pharmaceutical companies have achieved a number of successes; for example, Pfizer's Viagra for erectile dysfunction and Celgene's thalidomide for leprosy and multiple myeloma.
From reference 1, published 2014: "Drug repurposing is the use of an approved drug or a drug under development for a different indication than that for which it was originally developed. Drug repositioning has recently been used to describe the novel use of a drug that was previously discontinued for development. (For the purposes of this workshop summary) drug repurposing and repositioning are used interchangeably."
- Institute of Medicine (2014). Drug Repurposing and Repositioning: Workshop Summary. National Academies Press. ISBN 978-0-309-30204-3.
- Sleigh SH, Barton CL (23 August 2012). "Repurposing Strategies for Therapeutics". Pharmaceutical Medicine. 24 (3): 151–159. doi:10.1007/BF03256811.
- Ashburn TT, Thor KB (August 2004). "Drug repositioning: identifying and developing new uses for existing drugs". Nature Reviews. Drug Discovery. 3 (8): 673–83. doi:10.1038/nrd1468. PMID 15286734.
- Chong CR, Sullivan DJ (August 2007). "New uses for old drugs". Nature. 448 (7154): 645–6. doi:10.1038/448645a. PMID 17687303.
- Tartaglia LA (November 2006). "Complementary new approaches enable repositioning of failed drug candidates". Expert Opinion on Investigational Drugs. 15 (11): 1295–8. doi:10.1517/135437184.108.40.2065. PMID 17040191.
- Aronson JK (November 2007). "Old drugs--new uses". British Journal of Clinical Pharmacology. 64 (5): 563–5. doi:10.1111/j.1365-2125.2007.03058.x. PMC 2203255. PMID 17935601.
- Pritchard JL, O'Mara TA, Glubb DM (December 2017). "Enhancing the promise of drug repositioning through genetics". Frontiers in Pharmacology. 8: 896. PMID 29270124.